A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome

Brain Research

Volumn 741, Issue 1-2, 1996, Pages 142-152

  Gerlach, Manfred ^a   Gsell, Wieland ^a   Kornhuber, Johannes ^a   Jellinger, Kurt ^b   Krieger, Verena ^c   Pantucek, Felix ^c   Vock, Reinhard ^d   Riederer, Peter ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b GENERAL HOSPITAL LINZ   (Austria)

^c Landeskrankenhaus Mauer   (Austria)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

aminobutyric acid; basal ganglia; dopamine; glutamate; human; motor loop; N methyl D aspartate receptor; Parkinson's disease; Parkinsonian symptom

Indexed keywords

GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; GABAERGIC SYSTEM; HUMAN; HUMAN TISSUE; LOCOMOTION; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; THALAMUS;

3,4-DIHYDROXYPHENYLACETIC ACID; AGED; AGED, 80 AND OVER; BASAL GANGLIA; BIOLOGICAL MARKERS; CEREBRAL CORTEX; DOPAMINE; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HOMOVANILLIC ACID; HUMANS; KINETICS; MALE; MIDDLE AGED; NEURONS; PARKINSON DISEASE, SECONDARY; THALAMUS;

EID: 0030602076     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(96)00915-8     Document Type: Article

References (42)

1. [1] Albin, R.L., Young, A.B. and Penney, J.B., The functional anatomy of basal ganglia disorders, Trends Neurosci., 12 (1989) 366-375.
2. [2] Albin, R.L., Reiner, A., Andersen, K.D., Penney, J.B. and Young, A.B., Striatal and nigral neuron subpopulations in rigid Huntington's disesae: implications for the functional anatomy of chorea and rigidity-akinesia, Ann. Neurol., 27 (1990) 357-365.
3. [3] Alexander, G.E. and Crutcher, M.D., Functional architecture of basal ganglia circuits: neural substrates of parallel processing, Trends Neurosci., 13 (1990) 266-271.
4. 3H]kainate, Brain Res., 658 (1994) 209-218.
5. [5] Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F., Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations, J. Neurol. Sci., 20 (1973) 415-455.
6. [6] Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding, Anal. Biochem., 72 (1976) 248-254.
7. [7] Carlsson, M. and Carlsson, A., Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease, Trends Neurosci., 13 (1990) 272-276.
8. 3H]Nipecotic acid binding to γ-aminobutyric acid uptake sites in postmortem human brain, J. Neurochem., 55 (1990) 165-168.
9. [9] DeLong, M.R., Primate models of movement disorders of basal ganglia origin, Trends Neurosci., 13 (1990) 281-285.
10. [10] DeLorey, T.M. and Olsen R.W., GABA and glycine. In G.J. Siegel, B.W. Agranoff, R.W. Albers, and P.B. Molinoff (Eds.), Basic Neurochemistry: Molecular, Cellular, and Medical Aspects, 5th edn., Raven Press, New York 1994, pp. 389-399.
11. [11] Difazio, M.C., Hollingsworth, Z., Young, A.B. and Penney, J., Glutamate receptors in the substantia nigra of Parkinson's disease brains, Neurology, 42 (1992) 402-406.
12. [12] Dingledine, R. and McBain, C.J., Excitatory amino acid transmitters. In G.J. Siegel, B.W. Agranoff, R.W. Albers, and P.B. Molinoff (Eds.), Basic Neurochemistry: Molecular, Cellular, and Medical Aspects, 5th edn., Raven Press, New York 1994, pp. 367-387.
13. [13] Ehringer, H. and Hornykiewicz, O., Verteilung von Dopamin und Noradrenalin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems, Klin. Wochenschr., 38 (1960) 1236-1239.
14. [14] Ellison, D.W., Beal, M.F. and Martin, J.B., Amino acid neurotransmitters in postmortem human brain analyzed by high performance liquid chromatography with electrochemical detection, J. Neurosci. Methods, 19 (1987) 305-315.
15. [15] Fischer, P.A., Long-term course in Parkinson's syndrome and cerebral polypathy (Parkinson plus) Adv. Neurol., 45 (1987) 235-238.
16. [16] Fonnum, F., Glutamate: a neurotransmitter in mammalian brain, J. Neurochem., 42 (1984) 1-11.
17. [17] Gerlach, M. and Riederer, P., The pathophysiological basis of Parkinson's disease. In I. Szelenyi (Ed.), Inhibitors of Monoamine Oxidase B: Pharmacology and Clinical Use in Neurodegenerative Disorders., Birkhäuser, Basel/Boston/Berlin, 1993, pp. 25-50.
18. [18] Gerlach, M., Kornhuber, J., Lange, K.W. and Riederer, P., Neurochemical correlates of the interaction of dopaminergic, GABA-ergic and glutamatergic systems in the motor loop of patients with Parkinson's disease. 3rd International Congress on Amino Acids, Peptides and Analogues, August 23-27th 1993, Wien, Amino Acids, 5 (1993) 162.
19. [19] Gerlach, M., Gsell, W., Kornhuber, J., Lange, K.W. and Riederer, P., Neurochemical correlates of the interaction of dopaminergic, GABA-ergic and glutamatergic systems in the 'motor' loop of patients with Parkinson's disease. 11th International Symposium on Parkinson's Disease, March 26-30 1994, Rome, New Trends Clin. Neuropharmacol., 8 (1994) 57.
20. [20] Griffiths, P.D., Sambrook, M.A., Perry, R. and Crossman, A.R., Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease, J. Neurol. Sci., 100 (1990) 131-136.
21. [21] Gsell, W., Lange, K.W., Pfeuffer, R., Heckers, S., Heinsen, H., Senitz, D., Jellinger, K., Ransmayr, G., Wichart, I., Vock, R., Beckmann, H. and Riederer, P., How to run a brain bank: a report from the Austro-German brain bank, J. Neural Transm. (Suppl.), 39 (1993) 31-70.
22. [22] Hoehn, H.M. and Yahr, M.D., Parkinsonism: onset, progression and mortality, Neurology, 17 (1967) 427-442.
23. 3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive nuclear palsy, Brain Res., 565 (1991) 154-157.
24. [24] Jones, B.N., Pääbo, S. and Stein S., Amino acid analysis and enzymatic sequence determination of peptides by an improved o-phthalaldehyde precolumn labeling procedure, J. Liquid Chromatogr., 4 (1981) 565-585.
25. [25] Kish, S.J., Rajput, A., Gilbert, J., Rozdilsky, B., Chang, L.J., Shannak, K. and Hornykiewicz, O., Elevated-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss, Ann. Neurol., 20 (1986) 26-31.
26. [26] Korf, J. and Venema, K., Amino acids in the substantia nigra of rats with striatal lesions produced by kainic acid, J. Neurochem., 40 (1983) 1171-1173.
27. 3H]MK-801 binding sites in post-mortem human frontal cortex, Eur. J. Pharmacol., 162 (1989) 483-490.
28. [28] Kornhuber, J., Bormann, J., Hübers, M., Rusche, K. and Riederer, P., Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur. J. Pharmacol. - Mol. Pharmacol. Sect., 296 (1991) 297-300.
29. [29] Kornhuber, J., Quack, G., Danysz, W., Jellinger, K., Danielczyk, W., Gsell, W. and Riederer, P., Therapeutic brain concentration of the NMDA receptor antagonist amantadine, Neuropharmacology, 34 (1995) 713-721.
30. [30] Lodge, D. and Collingridge, G. (Eds.), The Pharmacology of Excitatory Amino Acids. A Trends Pharmacol. Sci. Special Report, Elsevier, Cambridge, 1990, pp. 1-3.
31. [31] Marmo, E., L-Glutamic acid as a neurotransmitter in the CNS, Med. Res. Rev., 8 (1988) 441-458.
32. [32] Marsden, C.D. and Obeso, J.A., Review article: the functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease, Brain, 117 (1994) 877-897.
33. [33] Nicholls, D.G., Sihra, T.S. and Sánchez-Prieto, J., Calcium-dependent and -independent release of glutamate from synaptosomes monitored by continuous fluorometry, J. Neurochem., 49 (1987) 50-57.
34. [34] Ossowska, K., The role of excitatory amino acids in experimental models of Parkinsons's disease, J. Neural Transm. (Park. Dem. Sect.), 8 (1994) 39-71.
35. [35] Paulus, W. and Jellinger, K., The neuropathologic basis of different clinical subgroups of Parkinson's disease, J. Neuropathol. Exp. Neurol., 50 (1991) 743-755.
36. [36] Perry, E.K., Perry, R.H. and Tomlinson, B.E., The influence of agonal states on some neurochemical activities of post-mortem human brain tissue, Neurosci. Lett., 29 (1982) 303-307.
37. [37] Reynolds, G.P. and Pearson, S.J., Measurement of γ-aminobutyric acid and glutamate in brain tissue. In R.B. Holman, A.J. Cross, and M.H. Joseph (Eds.), High Performance Liquid Chromatography in Neuroscience Research., John Wiley, New York, 1993, pp. 101-117.
38. [38] Storey, E. and Beal, M.F., Neurochemical substrates of rigidity and chorea in Huntington's disease, Brain, 116 (1993) 1201-1222.
39. [39] Toru, M., Watanabe, S., Shibuya, H., Nishikawa, T., Noda, K., Mitsushio, H., Ichikawa, H., Kurimaji, A., Takashima, M., Mataga, N. and Ogawa, A., Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients, Acta Psychol Scand., 78 (1988) 121-137.
40. [40] Wagner, J., Vitali, P., Palfreyman, M.G., Zraika, M. and Hout, S., Simultaneous determination of 3,4,-dihydroxyphenylalanine, 5-hydroxytryptophan, dopamine, 4-hydroxy-3-methoxyphenylalanine, norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillinic acid, serotonin, and 5-hydroxyindole acetic acid in rat cerebrospinal fluid and brain by high performance liquid chromatography with electrochemical detection, J. Neurochem., 38 (1982) 1241-1254.
41. [41] Weihmuller, F.B., Ulas, J., Nguyen, L., Cotman, C.W. and Marshall, J.F., Elevated NMDA receptors in Parkinsonian striatum, NeuroReport, 3 (1992) 977-980.
42. [42] Westbrook, G.L., Glutamate receptor update, Curr. Opin. Neurobiol., 4 (1994) 337-346.